{
    "Case ID": "044832",
    "Crime_Name": [
        "Patent Infringement/Invalidity"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent validity dispute"
    ],
    "Legal_Issue": [
        "Validity of Patent No. 2,209,735 for use of atomoxetine to treat ADHD"
    ],
    "Governing_Law": [
        "Patent Act"
    ],
    "Procedural_Stage": [
        "Trial"
    ],
    "Evidence_Assessment": [
        "MGH Study was too small and short-term to prove clinical utility; lack of disclosure of factual basis for sound prediction"
    ],
    "Decision_Outcome": [
        "'735 Patent declared invalid and void"
    ],
    "Burden_of_Proof": [
        "On Novopharm to establish invalidity"
    ],
    "Credibility_Factor": [
        "Expert testimonies on prior art and sufficiency of evidence"
    ],
    "Legal_Rule": [
        "Patent must demonstrate utility, novelty, and non-obviousness; utility requires demonstrated effectiveness or sound prediction"
    ],
    "Standard_of_Review": [
        "Balance of probabilities"
    ],
    "Procedural_Issue": [],
    "Grounds_for_Claim": [
        "Obviousness, anticipation, lack of disclosure, inutility"
    ],
    "Outcome_on_Merits": [
        "Patent found invalid due to inutility"
    ],
    "Decision_Maker": [
        "Trial court"
    ],
    "Judicial_Review_Outcome": [],
    "Review_Standard": [],
    "Procedural_Fairness_Assessment": [],
    "Key_Evidence_Considered": [
        "MGH Study, expert testimony, prior art"
    ],
    "Legal_Framework": [
        "Canadian patent law"
    ],
    "Applicant_Challenge": [
        "Novopharm challenged the validity of Lilly's patent"
    ],
    "Court_Result": [
        "Patent invalidated under Section 60(1) of the Patent Act"
    ],
    "Legal_Rule_Source": [
        "Patent Act, Section 60(1)"
    ],
    "Standard_of_Proof": [
        "Preponderance of evidence"
    ],
    "Defendant_Response": [
        "Lilly defended the validity of the '735 Patent"
    ],
    "Evidence_Type": [
        "Clinical study data, expert opinion, patent documentation"
    ],
    "Remedy_Requested": [
        "Declaration of patent invalidity"
    ],
    "Outcome": [
        "Patent declared invalid"
    ],
    "Decision_Authority": [
        "Trial court judge"
    ],
    "Remedy_Sought": [
        "Invalidation of the '735 Patent"
    ],
    "Resolution_Mechanism": [
        "Judicial trial"
    ],
    "Legal_Provision": [
        "Section 60(1) of the Patent Act"
    ],
    "Authority": [
        "Canadian courts"
    ],
    "Claimant_Status": [
        "Generic pharmaceutical company (Novopharm)"
    ],
    "Legal_Provision_Cited": [
        "Section 60(1), Patent Act"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Inutility, lack of sound prediction, insufficient disclosure"
    ],
    "Applicable_Process": [
        "Civil litigation"
    ],
    "Outcome_of_Review": [],
    "Pending_Relief_or_Application": [],
    "Jurisdiction": [
        "Canada"
    ],
    "Governing_Rule": [
        "Patent Act requirements for utility, novelty, and non-obviousness"
    ]
}